Published in Open Rheumatol J on December 30, 2011
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther (2013) 0.77
Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum (2006) 10.39
Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum (1997) 2.40
Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2004) 2.37
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest (2004) 2.34
Treatment recommendations for psoriatic arthritis. Ann Rheum Dis (2008) 1.85
Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum (2003) 1.82
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum (2001) 1.70
Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum (2000) 1.65
Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther (2005) 1.52
Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis (2008) 1.47
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis (2006) 1.39
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum (2004) 1.25
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22
Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum (2004) 1.12
Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis (2007) 1.11
IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol (2001) 1.11
Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09
Mortality in psoriatic arthritis. Clin Exp Rheumatol (2008) 1.08
Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. Am J Pathol (2008) 1.07
Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J Immunol (2009) 1.07
How to perform and analyse synovial biopsies. Best Pract Res Clin Rheumatol (2009) 1.06
Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol (2001) 1.03
Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis (2004) 1.03
Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol (2008) 0.98
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum (2005) 0.96
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis (2008) 0.95
Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol (2006) 0.93
Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go? Ann Rheum Dis (2005) 0.93
Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy. Ann Rheum Dis (2004) 0.92
Synovial tissue analysis in clinical trials. J Rheumatol (2005) 0.88
Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis. Ann Rheum Dis (2006) 0.87
Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol (1999) 0.87
Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis (2009) 0.83
Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. Ann Rheum Dis (2003) 0.80
The pathobiology of psoriatic synovium. Curr Opin Rheumatol (2008) 0.78
Fluctuation of circulating plasmacytoid dendritic cells in a patient with psoriatic arthritis. J Eur Acad Dermatol Venereol (2008) 0.77
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol (2010) 4.92
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 4.52
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol (2009) 3.41
MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A (2011) 3.37
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol (2007) 2.82
Interleukin-18. J Leukoc Biol (2003) 2.75
Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol (2010) 2.64
IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol (2007) 2.43
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37
A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol (2003) 2.37
Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail (2013) 2.17
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol (2010) 1.92
A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol (2004) 1.88
Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum (2013) 1.84
Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res (2010) 1.80
Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol (2012) 1.71
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis (2011) 1.63
IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis (2010) 1.62
Animal models of rheumatoid arthritis. Eur J Immunol (2009) 1.57
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med (2015) 1.56
A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol (2004) 1.55
25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis (2012) 1.46
The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 1.42
IL-33 exacerbates autoantibody-induced arthritis. J Immunol (2010) 1.40
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum (2008) 1.39
Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc Natl Acad Sci U S A (2009) 1.31
Optimization of current and future therapy for autoimmune diseases. Nat Med (2012) 1.29
Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis (2010) 1.28
Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med (2013) 1.26
IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-alpha and leukotriene B4. J Immunol (2003) 1.26
A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol (2002) 1.22
Ultrasound guided versus conventional joint and soft tissue fluid aspiration in rheumatology practice: a pilot study. J Rheumatol (2002) 1.21
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol (2013) 1.20
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis (2012) 1.19
Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum (2007) 1.19
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis (2012) 1.17
Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol (2013) 1.17
Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J Immunol (2009) 1.16
Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol (2008) 1.16
Inflammation is present in early human tendinopathy. Am J Sports Med (2010) 1.12
IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol (2011) 1.12
IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol (2011) 1.11
Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2012) 1.11
Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis? J Foot Ankle Res (2010) 1.11
Hypoxia: a critical regulator of early human tendinopathy. Ann Rheum Dis (2011) 1.10
Immune regulation in psoriasis and psoriatic arthritis--recent developments. Immunol Lett (2007) 1.10
Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther (2004) 1.10
Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol (2005) 1.10
Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum (2007) 1.08
Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J Immunol (2009) 1.07
Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. Am J Pathol (2008) 1.07
IL-15 mediates antigen-induced neutrophil migration by triggering IL-18 production. Eur J Immunol (2007) 1.06
A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Ann Rheum Dis (2012) 1.05
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis (2012) 1.05
Universal expression and dual function of the atypical chemokine receptor D6 on innate-like B cells in mice. Blood (2011) 1.04
MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One (2013) 1.04
Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol (2007) 1.02
TNF-blocking therapies: an alternative mode of action? Trends Immunol (2005) 1.02
Images in cardiovascular medicine. Multiphoton microscopy for 3-dimensional imaging of lymphocyte recruitment into apolipoprotein-E-deficient mouse carotid artery. Circulation (2007) 1.02
Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti-citrullinated peptide antibody titres. J Clin Periodontol (2013) 1.02
Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum (2013) 1.01
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol (2015) 1.00
Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol (2008) 0.99
Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol (2010) 0.99
Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol (2007) 0.98
Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis (2011) 0.98
Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol (2008) 0.97
Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol Cell Biol (2012) 0.96
Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum (2009) 0.96
An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis (2011) 0.95
Chemoattraction of human T cells by IL-18. J Immunol (2003) 0.95
A TLR2 ligand suppresses inflammation by modulation of chemokine receptors and redirection of leukocyte migration. Blood (2009) 0.95
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) (2013) 0.95
The role of innate mediators in inflammatory response. Mol Immunol (2002) 0.95
ES-62, a filarial nematode-derived immunomodulator with anti-inflammatory potential. Immunol Lett (2004) 0.94
Murine neutrophils present Class II restricted antigen. Immunol Lett (2008) 0.94
Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One (2012) 0.94
New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol (2006) 0.94
Inducing experimental arthritis and breaking self-tolerance to joint-specific antigens with trackable, ovalbumin-specific T cells. J Immunol (2004) 0.92
Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Expert Opin Biol Ther (2007) 0.92
Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J Immunol (2002) 0.91
A reliability study of biomechanical foot function in psoriatic arthritis based on a novel multi-segmented foot model. Gait Posture (2010) 0.90
Expression and alternative processing of IL-18 in human neutrophils. Eur J Immunol (2006) 0.90
Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. Am J Pathol (2012) 0.90
Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis. Rheumatology (Oxford) (2010) 0.90
Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol (2011) 0.90
Identifying the cells breaching self-tolerance in autoimmunity. J Immunol (2010) 0.89
Protease-activated receptor 2: a novel pathogenic pathway in a murine model of osteoarthritis. Ann Rheum Dis (2010) 0.89
What can the periodontal community learn from the pathophysiology of rheumatoid arthritis? J Clin Periodontol (2011) 0.89
Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis. Rheumatol Int (2011) 0.88